Loading...

23andMe Holding Co.

ME•NASDAQ
Healthcare
Medical - Diagnostics & Research
$4.96
$4.35(718.08%)

23andMe Holding Co. (ME) Stock Overview

Explore 23andMe Holding Co.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

C+

Score: 58.9/100

Key Financials

Market Cap13.3M
P/E Ratio-0.04
EPS (TTM)$-17.39
ROE-3.10%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$0.00
1 Year Target$1.72

ME Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of 23andMe Holding Co. (ME) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.72.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.04 and a market capitalization of 13.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for MEStats details for ME are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$0.42
Average$0.42
High$0.42

Company Profile

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

CEO

Joseph Selsavage

Employees

560

Headquarters

349 Oyster Point Boulevard, South San Francisco, CA

Founded

2020

Frequently Asked Questions

;